Propaten Randomized Investigation on Cost-benefit and Efficacy

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 103 participants.

Also called NCT01601873

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 103 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01601873
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01601873. Randomized; double masking; primary purpose treatment. Start 2012-11-09 (actual); primary completion 2017-12-31 (actual). Results posted on 2019-02-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Propaten Randomized Investigation on Cost-benefit and Efficacy
Acronym
PRICE
Condition
End-stage Renal Disease
Intervention (Device)
PROPATEN
Intervention (Device)
Standard Graft
Lead sponsor
The University of Texas Health Science Center, Houston (class: other)
Collaborator
University Hospitals Cleveland Medical Center (class: other)
Collaborator
University of Arkansas (class: other)
Collaborator
Ochsner Health System (class: other)

Record details

Record id
cardio:ct-nct01601873
Content hash
8a86a3967ab0de38f2887a83929d660558515e75c399b528cbbdf480c37f735b